What is the recommended daratumumab‑based treatment regimen, dosing, and administration schedule for a transplant‑ineligible patient with multiple myeloma?

Daratumumab-Based Treatment for Transplant-Ineligible Multiple Myeloma

For transplant-ineligible patients with newly diagnosed multiple myeloma, daratumumab plus lenalidomide and dexamethasone (DRd) is the preferred regimen, administered until disease progression or unacceptable toxicity. 1, 2

Recommended Regimen and Dosing

Daratumumab + Lenalidomide + Dexamethasone (DRd)

Daratumumab dosing schedule (16 mg/kg IV):

• Weeks 1-8: Weekly infusions (8 doses total)
• Weeks 9-24: Every 2 weeks (8 doses total)
• Week 25 onwards: Every 4 weeks until progression 2

Lenalidomide: 25 mg orally days 1-21 of each 28-day cycle 3

Dexamethasone: 40 mg on days 1,8,15, and 22 of each cycle 3

Clinical Evidence Supporting DRd

The MAIA trial demonstrated superior outcomes with DRd versus lenalidomide-dexamethasone alone in transplant-ineligible patients 3:

• Progression-free survival: 70.6% at 30 months with DRd vs 55.6% with Rd alone (HR 0.56, P<0.001)
• Complete response rate: 47.6% vs 24.9% (P<0.001)
• MRD negativity: 24.2% vs 7.3% (P<0.001)

This represents a 44% reduction in risk of progression or death with the addition of daratumumab 1.

Alternative Regimens

For Standard-Risk Disease

Bortezomib + Lenalidomide + Dexamethasone (VRd) for 8-12 cycles followed by lenalidomide maintenance is an acceptable alternative 4. However, recent guidelines have moved VRd from "preferred" to "other recommended" given DRd's superior outcomes 5.

For High-Risk Disease or Specific Situations

Isatuximab + Bortezomib + Lenalidomide + Dexamethasone (Isa-VRd) for patients <80 years who are not frail 5:

• Provides deeper responses with 53% MRD negativity at 18 months
• Consider for high-risk cytogenetics (double-hit or triple-hit myeloma) 4

Daratumumab + Bortezomib + Melphalan + Prednisone (D-VMP) as an alternative option 1, 2:

• 6-week cycles with weekly daratumumab for weeks 1-6
• Then every 3 weeks for weeks 7-54
• Then every 4 weeks from week 55 onwards 2

Administration Considerations

Infusion Protocol

• First infusion: Start at 50 mL/hour, escalate to maximum 200 mL/hour if tolerated
• Subsequent infusions: Can start at 100 mL/hour if no prior reactions, escalate to 200 mL/hour 2
• Infusion time: First dose typically 7+ hours; subsequent doses 3-4 hours

Pre-medications Required

• Corticosteroids (to reduce infusion reactions)
• Antihistamines
• Antipyretics 2

Post-infusion Prophylaxis

• Corticosteroids for 2 days following infusion 2

Essential Supportive Care

Mandatory prophylaxis:

• Herpes zoster prophylaxis for all patients receiving proteasome inhibitors 6, 4
• Thromboembolism prophylaxis: Full-dose aspirin for most patients; therapeutic anticoagulation for high-risk patients 6, 4
• Pneumocystis jiroveci prophylaxis for patients on dexamethasone 4
• Levofloxacin for first 2 cycles 4

Treatment Duration

Continue therapy until disease progression or unacceptable toxicity 4, 1. The MAIA trial demonstrated continued benefit with ongoing treatment, with median follow-up of 28 months showing sustained responses 3.

Common Pitfalls and Management

Hematologic Toxicity

• Neutropenia: Occurs in 50% (grade 3-4) with DRd vs 35.3% with Rd alone 3
• Monitor CBC regularly; dose reduce lenalidomide if needed

Infections

• Pneumonia: 13.7% (grade 3-4) with DRd vs 7.9% with Rd 3
• Maintain vigilant infection monitoring and prophylaxis

Infusion Reactions

• Occur in ~28% of patients, mostly with first infusion 7
• Pre-medication and slower initial infusion rates are critical
• Consider subcutaneous formulation if available to reduce infusion time and reactions 8

Blood Bank Interference

• Daratumumab interferes with blood typing and antibody screening 2
• Type and screen patients BEFORE starting daratumumab 2

Risk-Adapted Approach

Standard-risk patients: DRd until progression, then lenalidomide maintenance 4

High-risk patients (double/triple-hit cytogenetics): Consider quadruplet therapy with Isa-VRd or Dara-VRd, followed by bortezomib-based maintenance 4

Patients with pre-existing neuropathy: DRd is preferred over bortezomib-containing regimens 4

Patients with renal insufficiency: Consider daratumumab + cyclophosphamide + bortezomib + dexamethasone 5

The evidence strongly supports DRd as the optimal first-line therapy for transplant-ineligible patients, with superior survival outcomes and manageable toxicity when appropriate supportive care is provided 1, 3.